Spots Global Cancer Trial Database for BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
Official Title: A Phase II Study of BKM120; a Pan-PI3K Inhibitor in Patients With Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
Study ID: NCT01806649
Conditions
Interventions
Study Description
Brief Summary: There is a need for more effective therapy for patients with esophageal squamous cell carcinoma who developed disease progression after first line therapy. Currently, there is no standard second-line therapy for this disease. BKM-120 is a pan-PI3K inhibitor currently tested in clinical trials. In a cellular model of oral-esophageal carcinogenesis, it has shown that EGFR overexpression activated PI3/AKT pathway. Therfore, there is interest to see the efficacy and safety of BKM120 in this setting.
Detailed Description:
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Songklanagarind Hospital, Prince of Songkla University, Hat yai, Songkhla, Thailand
Contact Details
Name: Arunee Dechaphunkul, MD
Affiliation: Prince of Songkla University, Thailand
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
